Aphria Closes Upsized $86mm Equity Sale, the Largest Capital Raise in Canada to Date

Aphria Logo
Aphria Announces Closing of Bought Deal Financing

LEAMINGTON, ONTARIO–(Marketwired – May 9, 2017) –

Aphria Inc. (“Aphria” or the “Company”) (TSX: APH) (OTC: APHQF) is pleased to announceit has closed its short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriters’ over-allotment option. A total of 13,269,252 common shares (the “Shares”) of the Company were sold at a price of $6.50 per Share, for aggregate gross proceeds of $86,250,138 (the “Offering”). The Offering was underwritten by a syndicate of underwriters led by Clarus Securities Inc. and included Cormark Securities Inc., Canaccord Genuity Corp., and PI Financial Corp (collectively, the “Underwriters”).

50% of the net proceeds from the Offering will be allocated towards the currently unfunded portion of the planning, design, development, construction and implementation (including the purchase of certain designated capital equipment) of the Company’s’ Part IV Expansion. 10% of the net proceeds from the Offering will be allocated to the working capital necessary to support the Company once Part IV expansion is complete and the remaining 40% will be allocated towards strategic investments.

Until spent by the Company, a portion of the net proceeds of the Offering will be held as cash balances in the Company’s bank account and the remaining portion will be invested at the discretion of the Company’s Board of Directors.

The Shares were offered for sale in each of the provinces of Canada, other than the Province of Quebec, by short form prospectus, and in those jurisdictions outside of Canada and the United States which were agreed to by the Company and the Underwriters, where the Shares were issued on a private placement basis, exempt from any prospectus, registration or other similar requirements.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities of Aphria Inc. in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities offered have not been and will not be registered under the U.S. Securities Act or any U.S. state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or unless an exemption from such registration is available.

About Aphria

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters.

We Have a Good Thing Growing.

Original press release: http://www.marketwired.com/press-release/aphria-announces-closing-of-bought-deal-financing-otcqb-aphqf-2215040.htm

Before this cannabis stock news is here, it’s published to subscribers on 420 Investor.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. For questions contact us.


Get Our Sunday Newsletter